Should I buy Fisher & Paykel Healthcare stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Fisher & Paykel Healthcare for over three years. Every month, hundreds of thousands of users in Australia trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, paid by Fisher & Paykel Healthcare.

What is Fisher & Paykel Healthcare?

The Fisher & Paykel Healthcare Stock Price

The price of Fisher & Paykel Healthcare stock is down this week. The current share price sits at 33.70 AUD, with a 24-hour drop of 1.95% and positive annual movement of 23.72%. Market capitalisation stands at 19.78 billion AUD, with a 3-month average trading volume of 470,800. The stock displays a P/E Ratio of 56.89, a dividend yield of 1.24%, and a 5-year beta of 0.74, indicating moderate volatility. Given these figures, Fisher & Paykel Healthcare remains a prominent healthcare stock with strong growth momentum and international exposure.

Our full analysis of the Fisher & Paykel Healthcare stock

We have reviewed Fisher & Paykel Healthcare’s latest financial results, together with its share performance over the past three years. By blending leading financial indicators, technical signals, market data, and peer comparisons with our proprietary analytical algorithms, this report aims to provide a precise view of the opportunity. So, why might Fisher & Paykel Healthcare stock once again become a strategic entry point into the healthcare technology sector in 2025?

Recent performance and market context

Fisher & Paykel Healthcare (ASX: FPH) has demonstrated resilient performance, recently trading at 33.70 AUD per share, up 23.72% over the past year despite a mild -1.95% correction in its last session. This positive momentum follows the release of record financial results, surpassing 2.02 billion NZD in annual revenue—a 16% year-on-year jump. The May 2025 results offered reassurance to investors with a 43% surge in net profit, while expansion in the US and promising launches, such as the F&P Nova Nasal mask, have contributed to renewed buying interest.

This momentum is boosting the stock in a global landscape where healthcare innovation and defensive business models remain in high demand. The demographic tailwind of ageing populations and ongoing global demand for respiratory solutions positions Fisher & Paykel Healthcare at the heart of a sector benefiting from both macroeconomic stability and secular growth.

Technical analysis

On the technical front, Fisher & Paykel Healthcare is currently consolidating near its recent highs after a strong rally. The 14-day RSI stands at 40, signaling room for further upside as the stock is not overbought. Although the MACD remains slightly negative (-0.11), short-term corrections offer strategic entry points, given bullish signals from the 5-day moving average (buy), even as the 20-, 50-, and 200-day averages indicate room for renewed strength.

Key technical support levels are identified around 33.36–33.48 AUD, with immediate resistance at 33.86–33.98 AUD—suggesting the stock is at an inflection point. Continued buying volume and improving technical momentum could trigger a bullish reversal, ideally positioning investors ahead of the next major uptrend.

Fundamental analysis

From a fundamental viewpoint, Fisher & Paykel Healthcare’s 2025 numbers are nothing short of impressive. With revenue reaching 2.02 billion NZD and net profit leaping to 377.2 million NZD, the group confirms its ability to generate robust, recurring cash flows. The EBITDA margin also climbed, a testament to operational leverage and careful cost management.

The company’s P/E ratio, while elevated at 56.89 (trailing) and 50.76 (forward), is justified by above-sector growth, a robust innovation pipeline, and strong brand equity. Unlike pure-play hardware manufacturers, Fisher & Paykel Healthcare’s relentless investment in R&D (11% of revenue, over 226 million NZD in 2025) secures a structural leadership position in technological advancement. The hospital segment alone grew 18%, and homecare sales expanded by 13%—both critical to defend current multiples and suggest continued upward re-rating.

• Strong intellectual property portfolio and product differentiation.
• Worldwide sales across more than 120 countries, ensuring economies of scale.
• Resilient margins supported by product premiumisation and innovation.

Volume and liquidity

Trading volume—averaging 470,800 shares over three months—reflects consistent institutional interest and robust liquidity. This, coupled with a market cap of 19.78 billion AUD, facilitates dynamic and orderly price discovery. The healthy free float, bolstered by a 33.39% institutional holding, supports the ability for valuation multiple expansion on stronger results or positive news.

Catalysts and positive outlook

• Expansion of the F&P Airvo™ 3 and F&P 950™ systems in new markets, notably the US.
• Launch of innovative products, such as the Nova Nasal mask, addressing sleep apnoea—a market forecast to grow strongly worldwide.
• Ongoing 20% growth in consumables and 14% in masks, delivering incremental revenue streams and margin tailwinds.
• Record investments in R&D will likely yield further breakthrough products in coming years.
• ESG—commitment to sustainable production and global health access bolsters the stock’s standing among new-generation, responsible investors.
• Strategic geographic expansion and an established, diversified hospital/homecare product mix provide multiple levers for future growth.

With consensus forecasts targeting up to 2.25 billion NZD revenue for 2026 and ongoing net profit increases, these dynamics enable Fisher & Paykel Healthcare to command a premium but sustainable valuation.

Investment strategies

For short-term traders, potential retracements towards technical support levels (33.36–33.48 AUD) offer tactical entry points, especially when paired with bullish technical reversals or volume spikes.

Medium-term investors may consider positioning ahead of major product launches, quarterly earnings releases, or macro catalysts—such as demographic data or healthcare reimbursement changes that historically move the stock.

• Double-digit projected annual earnings and revenue growth.
• Repeat business from consumables and replacement cycles within the installed base.
• A defensive business model combining strong dividends (current yield ~1.24%) and resilient sector fundamentals.
• Structural ESG appeal, critical for future institutional and index inclusion.

This multifaceted opportunity profile suggests the stock is well-placed for multiple styles of investment, from growth through to quality and income strategies.

Is it the right time to buy Fisher & Paykel Healthcare?

In summary, Fisher & Paykel Healthcare stands out with its formidable blend of strong financials, global market leadership, relentless innovation, and resilient earnings profile. Current technical consolidation appears to represent an excellent opportunity for tactical and strategic entry, especially as the company continues to deliver above-market growth.

All indicators point toward a sustained or renewed bullish phase, with financial metrics and market signals both justifying renewed interest. With an expanding addressable market, new innovations entering commercialisation, and substantial investor confidence, Fisher & Paykel Healthcare seems poised for further upside in the remainder of 2025 and beyond. For investors seeking exposure to a world-class healthcare innovator, the stock’s underlying strengths and emerging catalysts strongly argue for serious consideration as a core portfolio holding.

How to buy Fisher & Paykel Healthcare stock in Australia

Buying Fisher & Paykel Healthcare stock online is straightforward and secure when using a regulated Australian broker. Investors can opt for a cash (spot) purchase, which means direct ownership of the shares, or trade using Contracts for Difference (CFDs) for leveraged exposure. Both methods are accessible online with transparent fees, allowing you to tailor your approach to your financial goals. To find the best conditions, take a look at the broker comparison further down the page.

Spot buying

A cash purchase of Fisher & Paykel Healthcare stock means you buy and directly hold actual shares in your trading account. Most Australian brokers charge a fixed commission per order, typically around $5 to $10 AUD per transaction.

Gain scenario

For example, if the Fisher & Paykel Healthcare share price is $33.70 AUD, you can buy around 29 shares with a $1,000 stake, including a brokerage fee of around $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading on Fisher & Paykel Healthcare shares allows you to speculate on the price movement without owning the underlying shares. Fees are based on the spread (the difference between buy/sell prices) and overnight financing if the position is held beyond a day.

Gain scenario

For example, you open a CFD position on Fisher & Paykel Healthcare shares, with 5x leverage and a $1,000 stake. This gives you a market exposure of $5,000.

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before investing, it’s essential to compare brokers’ fees and trading conditions to find what’s best for you. Your choice between spot buying and CFDs should reflect your risk tolerance, trading style, and financial goals. To help you decide, a broker comparison tool is available further down the page.

Our 7 tips for buying Fisher & Paykel Healthcare stock

The latest news about Fisher & Paykel Healthcare

Fisher & Paykel Healthcare delivered a record annual dividend of 42.5 cents per share, paid July 4th. Australian shareholders benefited from this robust payout, which is supported by strong cash flows and eligible for local investment schemes, increasing the stock’s attractiveness for income-focused portfolios.

ASX trading volume for Fisher & Paykel Healthcare averaged 470,800 shares over the last three months. Market activity remains solid, indicating healthy liquidity and sustained interest from Australian institutional and retail investors, even in periods of short-term technical pullbacks.

The company’s full-year financial results surpassed consensus with AUD 19.78 billion market capitalisation. A 16% increase in annual revenue and a 43% jump in net profit demonstrate business strength that resonates with AU investors, highlighting the resilience of its respiratory and intensive care product segments.

Fisher & Paykel Healthcare maintains a strategic local footprint with products distributed Australia-wide. Its respiratory and sleep apnoea solutions are widely used in Australian hospitals and homecare, benefiting from established distributor relationships and alignment with local healthcare policies.

Consensus 2026 forecasts project continued growth, supporting optimistic sentiment among Australian analysts. Official projections expect annual profit and revenue to grow 13.5% and 10.1%, respectively, bolstered by innovation, ongoing R&D investment, and favourable demographic trends across the AU healthcare market.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.